Tango Therapeutics, Inc. (TNGX)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 4
Do Nothing: company.price 26.23 (input snapshot; live last 26.2711) is above the $25.00 price ceiling for this strategy, and fundamentals.fundamentalScore is 2 (below the required floor of 3) — the chart's five-session momentum thrust above every moving average with a fresh MACD cross cannot be traded here; no breakout stop or pullback limit was evaluated because Step 03 is skipped on a hard-block gate failure.
Company overview
Tango Therapeutics, Inc. is a biotechnology company focused on developing cancer treatments. Its lead candidate, TNG908, targets PRMT5 for cancers with MTAP deletions. The company also works on therapies for BRCA1/2 and STK11-mutant cancers, in partnership with Gilead Sciences.
Fundamental
weakTango Therapeutics shows no revenue and significant losses, offset by a strong cash position and no debt.
Pre-revenue clinical-stage oncology company with zero revenue in 2026, a trailing net loss near $208 million and negative free cash flow, offset by a fortress balance sheet of $977.5 million in cash and marketable securities, no debt, no going-concern or covenant issues, and a multi-year runway. Valuation and cash-flow returns read deeply negative while 82 percent response-rate pancreatic data and a consensus target near double the share price carry the story. Weak financials, elevated binary clinical and dilution risk.
Sentiment
fairSentiment is mixed with positive clinical data but offset by insider sales and no near-term catalysts.
Dominant driver is the 2026-11-09 Q3 print and business update (announced) — vopimetostat plus daraxonrasib at 82% ORR and an 88% nine-month PFS rate in MTAP-deleted PDAC with a registrational Phase 3 guided to 1H 2027 and $977.5M of cash — received net-positively in the scored items and by post-print sell-side price-target revisions, though it is partially priced after the 2026-10-23 ESMO sell-off and there is no scheduled driver inside 30 days. The 30–90-day baseline came back below the three-unique-item threshold so the sentiment delta is indeterminate, and the legal/regulatory and Red-Flag screens came back clean of both severe and moderate flags, so no cap applies to this mixed, forming setup.
Technical
goodThe stock shows strong momentum above key moving averages but lacks a sustained trend.
Short-term tape is a strong momentum thrust: five consecutive up sessions from the 20.87 close on 2026-11-05 to 26.32 on 2026-11-11 (+26%), with price now above sma20 23.41, sma50 23.43, sma200 22.76, ema9 23.51 and ema21 23.34, and the MACD line crossing to +0.01 above its -0.25 signal (histogram +0.27) with RSI14 59.99. The weak links are trend persistence and short-term extension: ADX14 11.23 says there is no established directional trend behind the move, Williams %R -1.50 is maximally overbought right after a five-session run, and ATR14 1.96 (7.47% of price) means one ordinary session can retrace most of the breakout. Chart score 4 for the thrust itself, but no trade is available: the entry is blocked by the $25.00 price ceiling (input snapshot 26.23, live last 26.2711) and independently by fundamentalScore 2 < 3, so setupType resolves to no_setup and the action is Do Nothing.
You’re looking at 2026-11-11 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

